完善的ELN 2024风险分层改善了基于venetoclax疗法的急性髓细胞白血病患者的生存预后。

IF 21 1区医学 Q1 HEMATOLOGY

Blood Pub Date : 2024-11-01 DOI:10.1182/blood.2024026925

Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N Saultz, Jeffrey W Tyner, Richard James Dillon, Joshua F Zeidner, Daniel A Pollyea

{"title":"完善的ELN 2024风险分层改善了基于venetoclax疗法的急性髓细胞白血病患者的生存预后。","authors":"Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N Saultz, Jeffrey W Tyner, Richard James Dillon, Joshua F Zeidner, Daniel A Pollyea","doi":"10.1182/blood.2024026925","DOIUrl":null,"url":null,"abstract":"The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates re-classification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.","PeriodicalId":9102,"journal":{"name":"Blood","volume":null,"pages":null},"PeriodicalIF":21.0000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.\",\"authors\":\"Curtis A Lachowiez, Vishvaas I Ravikumar, Jad Othman, Jenny O'Nions, Daniel T Peters, Christine McMahon, Ronan Swords, Rachel Cook, Jennifer N Saultz, Jeffrey W Tyner, Richard James Dillon, Joshua F Zeidner, Daniel A Pollyea\",\"doi\":\"10.1182/blood.2024026925\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates re-classification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.\",\"PeriodicalId\":9102,\"journal\":{\"name\":\"Blood\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Blood\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1182/blood.2024026925\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/blood.2024026925","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

最近发布了针对接受低甲基化药物联合 Venetoclax 治疗的急性髓性白血病患者的 ELN 2024 风险分级指南。这项分析表明，在目前的模型中重新分类并纳入新的基因突变，可以进一步改善预后并使之个体化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML.

The ELN 2024 risk-stratification guidelines for patients with acute myeloid leukemia receiving hypomethylating agents combined with venetoclax were recently published. This analysis demonstrates re-classification and incorporation of new gene mutations in the present model can further improve and individualize prognostication.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Blood 医学-血液学

CiteScore

23.60

自引率

3.90%

发文量

955

审稿时长

1 months

期刊介绍： Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.